150 related articles for article (PubMed ID: 30517092)
1. Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors.
Yousuf M; Shaikh NN; Ul-Haq Z; Choudhary MI
PLoS One; 2018; 13(12):e0200502. PubMed ID: 30517092
[TBL] [Abstract][Full Text] [Related]
2. Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors.
Yousuf M
Curr Cancer Drug Targets; 2019; 19(11):906-918. PubMed ID: 30894110
[TBL] [Abstract][Full Text] [Related]
3. 2,5-Disubstituted thiadiazoles as potent β-glucuronidase inhibitors; Synthesis, in vitro and in silico studies.
Taha M; Barak Almandil N; Rashid U; Ali M; Ibrahim M; Gollapalli M; Mosaddik A; Mohammed Khan K
Bioorg Chem; 2019 Oct; 91():103126. PubMed ID: 31349116
[TBL] [Abstract][Full Text] [Related]
4. Biology-oriented drug synthesis (BIODS): In vitro β-glucuronidase inhibitory and in silico studies on 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives.
Salar U; Khan KM; Taha M; Ismail NH; Ali B; Qurat-Ul-Ain ; Perveen S; Ghufran M; Wadood A
Eur J Med Chem; 2017 Jan; 125():1289-1299. PubMed ID: 27886546
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and β-glucuronidase inhibitory potential of benzimidazole derivatives.
Khan KM; Khan M; Ambreen N; Rahim F; Naureen S; Perveen S; Choudhary MI; Voelter W
Med Chem; 2012 May; 8(3):421-7. PubMed ID: 22530898
[TBL] [Abstract][Full Text] [Related]
6. Discovery of specific inhibitors for intestinal E. coli β-glucuronidase through in silico virtual screening.
Cheng TC; Chuang KH; Roffler SR; Cheng KW; Leu YL; Chuang CH; Huang CC; Kao CH; Hsieh YC; Chang LS; Cheng TL; Chen CS
ScientificWorldJournal; 2015; 2015():740815. PubMed ID: 25839056
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bisindole as potent β-glucuronidase inhibitors: synthesis and in silico based studies.
Khan KM; Rahim F; Wadood A; Taha M; Khan M; Naureen S; Ambreen N; Hussain S; Perveen S; Choudhary MI
Bioorg Med Chem Lett; 2014 Apr; 24(7):1825-9. PubMed ID: 24602903
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis and biological evaluation of β-glucuronidase inhibitors.
Khan KM; Ambreen N; Taha M; Halim SA; Zaheer-ul-Haq ; Naureen S; Rasheed S; Perveen S; Ali S; Choudhary MI
J Comput Aided Mol Des; 2014 May; 28(5):577-85. PubMed ID: 24771145
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, in vitro β-glucuronidase inhibitory activity and in silico studies of novel (E)-4-Aryl-2-(2-(pyren-1-ylmethylene)hydrazinyl)thiazoles.
Salar U; Khan KM; Syed S; Taha M; Ali F; Ismail NH; Perveen S; Wadood A; Ghufran M
Bioorg Chem; 2017 Feb; 70():199-209. PubMed ID: 28069264
[TBL] [Abstract][Full Text] [Related]
10. New classes of potent heparanase inhibitors from ligand-based virtual screening.
Pala D; Scalvini L; Elisi GM; Lodola A; Mor M; Spadoni G; Ferrara FF; Pavoni E; Roscilli G; Milazzo FM; Battistuzzi G; Rivara S; Giannini G
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1685-1696. PubMed ID: 32907434
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase.
Palakurti R; Vadrevu R
Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354
[TBL] [Abstract][Full Text] [Related]
12. 2-Oxo-1,2,3,4-tetrahydropyrimidines Ethyl Esters as Potent β- Glucuronidase Inhibitors: One-pot Synthesis, In vitro and In silico Studies.
Iqbal S; Shaikh NN; Khan KM; Naz S; Ul-Haq Z; Perveen S; Choudhary MI
Med Chem; 2018; 14(8):818-830. PubMed ID: 29793412
[TBL] [Abstract][Full Text] [Related]
13. Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
Gozalbes R; Mosulén S; Ortí L; Rodríguez-Díaz J; Carbajo RJ; Melnyk P; Pineda-Lucena A
Bioorg Med Chem; 2013 Apr; 21(7):1944-51. PubMed ID: 23415087
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in silico studies of novel sulfonamides having oxadiazole ring: As β-glucuronidase inhibitors.
Taha M; Baharudin MS; Ismail NH; Selvaraj M; Salar U; Alkadi KA; Khan KM
Bioorg Chem; 2017 Apr; 71():86-96. PubMed ID: 28160943
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of flavonoids as natural inhibitors against E. coli β-glucuronidase.
Weng ZM; Wang P; Ge GB; Dai ZR; Wu DC; Zou LW; Dou TY; Zhang TY; Yang L; Hou J
Food Chem Toxicol; 2017 Nov; 109(Pt 2):975-983. PubMed ID: 28347758
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Molecular Docking and β-Glucuronidase Inhibitory Potential of Indole Base Oxadiazole Derivatives.
Anouar EH; Moustapha ME; Taha M; Geesi MH; Farag ZR; Rahim F; Almandil NB; Farooq RK; Nawaz M; Mosaddik A
Molecules; 2019 Mar; 24(5):. PubMed ID: 30857263
[TBL] [Abstract][Full Text] [Related]
17. Identify old drugs as selective bacterial β-GUS inhibitors by structural-based virtual screening and bio-evaluations.
Chen Z; Xu X; Piao L; Chang S; Liu J; Kong R
Chem Biol Drug Des; 2020 Mar; 95(3):368-379. PubMed ID: 31834987
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of benzimidazole derivatives as potent β-glucuronidase inhibitors.
Taha M; Ismail NH; Imran S; Selvaraj M; Rashwan H; Farhanah FU; Rahim F; Kesavanarayanan KS; Ali M
Bioorg Chem; 2015 Aug; 61():36-44. PubMed ID: 26073618
[TBL] [Abstract][Full Text] [Related]
19. Identification of potent inhibitors of DNA methyltransferase 1 (DNMT1) through a pharmacophore-based virtual screening approach.
Krishna S; Shukla S; Lakra AD; Meeran SM; Siddiqi MI
J Mol Graph Model; 2017 Aug; 75():174-188. PubMed ID: 28582695
[TBL] [Abstract][Full Text] [Related]
20. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
